SLC5A2 and chronic kidney disease: Analyses of cardiovascular outcomes were limited by lower than expected numbers of events, perhaps due to recruitment of low risk populations or secular trends towards lower cardiovascular risk.28 This was also a feature of the DAPA-CKD trial which leaves some uncertainty about cardiovascular effects of SGLT2 inhibitors in patients with CKD without diabetes.